• Genzyme (Cambridge, Massachusetts) reported the availability of two new molecular tests for acute myelogenous leukemia with the launch of FLT3 Mutation Analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. Designed to detect minimal residual disease, the WT1 RQ PCR test allows physicians to monitor AML patients for early relapse during and following therapy. Together, these tests may enable oncologists to better manage their patients, the company said.

• LI-COR Biosciences (Lincoln, Nebraska), a manufacturer of integrated infrared instrument systems and reagents, reported the introduction of IRDye Western kits for the Odyssey Infrared Imaging System. The kits feature IRDye 800 CW and IRDye 680 labeled secondary antibodies, Odyssey Blocking Buffer and PVDF membranes. The company also is introducing six new IRDye 700 oligos for gel shift assays (EMSAs) and a new EMSA Buffer kit optimized for use on the Odyssey system. The company said the infrared-dye based oligos offer distinct advantages over radioisotopes including long-term dye stability, rapid detection, and the flexibility to extend gel run times.

No Comments